Suppr超能文献

澳大利亚慢性非癌痛患者自述获得持续处方类阿片类药物的挑战。

Self-reported challenges obtaining ongoing prescription opioids among Australians with chronic non-cancer pain.

机构信息

National Drug and Alcohol Research Centre, UNSW Sydney, King St, Randwick, NSW, 2031, Australia.

School of Health and Behavioural Sciences, University of the Sunshine Coast, Sippy Downs Dr, Sippy Downs, QLD, 4556, Australia.

出版信息

Int J Drug Policy. 2022 Jul;105:103708. doi: 10.1016/j.drugpo.2022.103708. Epub 2022 May 8.

Abstract

BACKGROUND

Policies to address opioid-related harms include strategies to reduce opioid prescribing for new and ongoing pain management. Concerns have been raised that people with chronic non-cancer pain (CNCP) may be adversely affected by prescribing restrictions, and by involuntary tapering and cessation of opioids. We describe self-reported challenges obtaining prescription opioids among people prescribed opioids long-term for CNCP and explore associations with participant and treatment characteristics.

METHODS

This cross-sectional study analysed data from a longitudinal cohort study of Australians prescribed restricted opioids for CNCP. In 2018, 861 participants who took part in Year 5 follow-up and who also reported past 12-month opioid use were asked about challenges obtaining opioid prescriptions, including prescriber access-related difficulties obtaining prescriptions or having opioids tapered or ceased involuntarily. Associations between challenges and demographics, treatment characteristics including daily opioid dose as oral morphine equivalent milligrams (OME mg/day), substance use disorder (SUD), and opioid dependence were assessed.

RESULTS

Overall, 285 (31%) participants reported at least one challenge, predominantly prescriber access-related difficulties (n=177/285; 62%). Prescriber access-related difficulties were associated with younger age (adjustedOR 0.94 per year increase, 95%CI 0.93-0.96), and past 12-month pharmaceutical opioid dependence (adjustedOR 2.25, 95%CI 1.33-3.80). Involuntary opioid tapering or cessation was reported by 73 participants (26% of those reporting challenges) and was associated with lifetime SUD diagnosis (adjustedOR 2.15, 95%CI 1.15-3.90), and opioid doses of ≥200 OME mg/day (adjustedOR 2.41, 95%CI 1.18-4.88).

CONCLUSION

One-third of participants with CNCP reported experiencing challenges obtaining prescriptions for opioids or having their opioid medicines involuntarily reduced. Given increasing restrictions to opioid access, it is important that strategies to reduce opioid-related harms are balanced against the current treatment needs of people prescribed opioids long-term for CNCP.

摘要

背景

解决阿片类药物相关危害的政策包括减少新的和持续的疼痛管理中阿片类药物处方的策略。有人担心,慢性非癌症疼痛(CNCP)患者可能会受到处方限制以及阿片类药物的非自愿减少和停药的不利影响。我们描述了长期接受 CNCP 阿片类药物治疗的患者在获得处方阿片类药物方面的自我报告挑战,并探讨了与参与者和治疗特征的关联。

方法

这项横断面研究分析了一项针对澳大利亚慢性非癌症疼痛患者开具限制类阿片类药物的纵向队列研究的数据。在 2018 年,参加了第 5 年随访且报告过去 12 个月内使用过阿片类药物的 861 名参与者被问及获得阿片类药物处方的挑战,包括与处方医生相关的获取处方或使阿片类药物非自愿减少或停药的困难。评估了挑战与人口统计学特征、治疗特征(包括口服吗啡等效毫克数(OME mg/天)的每日阿片类药物剂量、物质使用障碍(SUD)和阿片类药物依赖)之间的关联。

结果

总体而言,285 名(31%)参与者报告了至少一项挑战,主要是与处方医生相关的获取处方困难(n=177/285;62%)。与年龄较小(调整后的 OR 每年增加 0.94,95%CI 0.93-0.96)和过去 12 个月药物阿片类药物依赖(调整后的 OR 2.25,95%CI 1.33-3.80)相关。73 名参与者(报告挑战的参与者的 26%)报告了非自愿的阿片类药物减量或停药,与终生 SUD 诊断(调整后的 OR 2.15,95%CI 1.15-3.90)和≥200 OME mg/天的阿片类药物剂量(调整后的 OR 2.41,95%CI 1.18-4.88)相关。

结论

三分之一的 CNCP 患者报告在获得阿片类药物处方或非自愿减少阿片类药物治疗方面存在挑战。鉴于阿片类药物获取限制的增加,在减少阿片类药物相关危害的策略与长期接受阿片类药物治疗的 CNCP 患者的当前治疗需求之间取得平衡非常重要。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验